Overview of clinical, molecular, and therapeutic features of Niemann–Pick disease (types A, B, and C): Focus on therapeutic approaches
- 7 May 2024
- journal article
- review article
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (4) , e4028
Abstract
Niemann–Pick disease (NPD) is another type of metabolic disorder that is classified as lysosomal storage diseases (LSDs). The main cause of the disease is mutation in the SMPD1 (type A and B) or NPC1 or NPC2 (type C) genes, which lead to the accumulation of lipid substrates in the lysosomes of the liver, brain, spleen, lung, and bone marrow cells. This is followed by multiple cell damage, dysfunction of lysosomes, and finally dysfunction of body organs. So far, about 346, 575, and 30 mutations have been reported in SMPD1, NPC1, and NPC2 genes, respectively. Depending on the type of mutation and the clinical symptoms of the disease, the treatment will be different. The general aim of the current study is to review the clinical and molecular characteristics of patients with NPD and study various treatment methods for this disease with a focus on gene therapy approaches.Keywords
This publication has 145 references indexed in Scilit:
- Gene therapy approaches for GM1 gangliosidosis: Focus on animal and cellular studiesCell Biochemistry and Function, 2023
- Pediatric hepatocellular carcinoma associated with Niemann–Pick disease type C: Case report and literature reviewJIMD Reports, 2022
- Types A and B Niemann‐Pick Disease2022
- Efficacy and safety of arimoclomol in Niemann‐Pick disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatmentJournal of Inherited Metabolic Disease, 2021
- Clinical, biochemical, and genotype‐phenotype correlations of 118 patients with Niemann‐Pick disease Types A/BHuman Mutation, 2021
- Association of Miglustat With Swallowing Outcomes in Niemann-Pick Disease, Type C1JAMA Neurology, 2020
- Long‐term survival outcomes of patients with Niemann‐Pick disease type C receiving miglustat treatment: A large retrospective observational studyJournal of Inherited Metabolic Disease, 2020
- SMPD1 Mutation Update: Database and Comprehensive Analysis of Published and Novel VariantsHuman Mutation, 2015
- Randomized, controlled trial of miglustat in Gaucher's disease type 3Annals of Neurology, 2008
- Correction of enzyme levels with allogeneic hematopoeitic progenitor cell transplantation in Niemann‐Pick type BPediatric Blood & Cancer, 2007